EXEL: Disciplined innovation and franchise expansion drive growth, with zanzalintinib poised for major launches
Revised summary: The discussion emphasized disciplined innovation, focusing on novel assets, AI-driven analytics, and franchise-building. Cabozantinib's growth and exclusivity support the shift to zanzalintinib, advancing in pivotal CRC, RCC, and NET trials. Regulatory, policy, and competitive risk…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.